CA2571692A1 - Biomarkers of alzheimer's disease - Google Patents

Biomarkers of alzheimer's disease Download PDF

Info

Publication number
CA2571692A1
CA2571692A1 CA002571692A CA2571692A CA2571692A1 CA 2571692 A1 CA2571692 A1 CA 2571692A1 CA 002571692 A CA002571692 A CA 002571692A CA 2571692 A CA2571692 A CA 2571692A CA 2571692 A1 CA2571692 A1 CA 2571692A1
Authority
CA
Canada
Prior art keywords
gsk
antibody
disease
alzheimer
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002571692A
Other languages
English (en)
French (fr)
Inventor
Simon Lovestone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King's College London
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2571692A1 publication Critical patent/CA2571692A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002571692A 2004-07-02 2005-07-01 Biomarkers of alzheimer's disease Abandoned CA2571692A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0414894.6A GB0414894D0 (en) 2004-07-02 2004-07-02 Biomarkers of alzheimer's disease
GB0414894.6 2004-07-02
PCT/GB2005/002592 WO2006003414A2 (en) 2004-07-02 2005-07-01 Biomarkers of alzheimer's disease

Publications (1)

Publication Number Publication Date
CA2571692A1 true CA2571692A1 (en) 2006-01-12

Family

ID=32843494

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002571692A Abandoned CA2571692A1 (en) 2004-07-02 2005-07-01 Biomarkers of alzheimer's disease

Country Status (9)

Country Link
US (1) US20080076140A1 (enExample)
EP (1) EP1763674A2 (enExample)
JP (1) JP2008504551A (enExample)
CN (1) CN101010589A (enExample)
AU (1) AU2005258926A1 (enExample)
BR (1) BRPI0512948A (enExample)
CA (1) CA2571692A1 (enExample)
GB (1) GB0414894D0 (enExample)
WO (1) WO2006003414A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2029503B1 (en) 2006-05-25 2013-01-02 GE Healthcare Limited 11c-labeled inhibitors of glycogen synthase kinase-3
WO2009074331A2 (en) * 2007-12-11 2009-06-18 Julius-Maximilians-Universität Würzburg Early and differential diagnosis test for alzheimer's disease
CA2718955C (en) 2008-03-21 2015-10-13 Manuela G. Neuman Methods and kits for the differential diagnosis of alzheimer's disease versus frontotemporal dementia and for the diagnosis of frontotemporal dementia comprising fas-l and ck 18 as biomarkers
US20100151457A1 (en) * 2008-12-17 2010-06-17 National Tsing Hua University Detection of Unhealthy Cell and Uses Thereof
US20120040361A1 (en) * 2010-07-22 2012-02-16 National Tsing Hua University Methods and compositions for detection of lethal system and uses thereof
CN104237526B (zh) * 2013-06-18 2016-08-17 磁量生技股份有限公司 一种检测阿兹海默症罹患风险的系统
CA2941650A1 (en) * 2014-03-05 2015-09-11 Humanetics Corporation Predicting and reducing cognitive decline based on gsk-3 levels
CN104698188A (zh) * 2015-03-04 2015-06-10 华中科技大学 检测人血小板GSK-3β蛋白活性的斑点印迹方法
CN111323597A (zh) * 2018-12-14 2020-06-23 陈志成 用于检测受试者中mci和/或ad的方法、试剂盒及筛选化合物的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766022A4 (en) * 2004-05-07 2007-07-11 Garvan Inst Med Res DETECTION OF A DISEASE ASSOCIATED WITH BERROROUS EXPRESSION OF GLYCENE SYNTHASE KINASE 3 BETA

Also Published As

Publication number Publication date
WO2006003414A3 (en) 2006-03-16
JP2008504551A (ja) 2008-02-14
AU2005258926A1 (en) 2006-01-12
US20080076140A1 (en) 2008-03-27
WO2006003414A2 (en) 2006-01-12
CN101010589A (zh) 2007-08-01
BRPI0512948A (pt) 2008-04-15
GB0414894D0 (en) 2004-08-04
EP1763674A2 (en) 2007-03-21

Similar Documents

Publication Publication Date Title
US9726678B2 (en) Methods and compositions for the diagnosis and prognosis of Alzheimer's disease
Erikson et al. Elevated serum S‐100β in patients with septic shock is associated with delirium
Diamandis et al. Human kallikrein 6 as a biomarker of Alzheimer’s disease
Ibach et al. Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample
Kiđemet‐Piskač et al. Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia
KR102198869B1 (ko) 잠재적 염증, 특히 이식 거부반응과 연관된 잠재적 염증, 신경변성 장애 또는 우울증의 조기 검출을 위한 시험관 내 방법
AU2016240409A1 (en) Method for predicting risk of cognitive deterioration
Bartosik‐Psujek et al. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone
Youn et al. Urine neural thread protein measurements in Alzheimer disease
WO2018221212A1 (ja) アルツハイマー病バイオマーカー
CA2718955C (en) Methods and kits for the differential diagnosis of alzheimer's disease versus frontotemporal dementia and for the diagnosis of frontotemporal dementia comprising fas-l and ck 18 as biomarkers
US20080076140A1 (en) Biomarkers of Alzheimer's Disease
US20240142471A1 (en) Test for mild cognitive impairment
EP3872494A1 (en) Blood biomarker for detecting deposition of amyloid beta in brains of groups with normal cognitive function and mild cognitive impairment
WO2015019979A1 (ja) 統合失調症に関するバイオマーカー
WO2013098786A1 (en) Method for the in vitro diagnosis of parkinson's disease
US20060205024A1 (en) Method to diagnose and evaluate progression of Alzheimer's disease
JP2005304476A (ja) ポリアミン、アクロレインの含有量又はポリアミンオキシダーゼ活性又はその蛋白質量を指標とした脳卒中・無症候性脳梗塞の診断方法
EP2642292A1 (en) Method for testing for cerebral infarction via cartilage acidic protein 1
JP2025016807A (ja) 脳内アミロイドβの蓄積を評価するためのバイオマーカー
RU2821893C1 (ru) Способ дифференциальной прижизненной диагностики болезни альцгеймера
US9784739B2 (en) Regulatory brain specific cytoplasmic RNAS (BC RNAs) and methods of use thereof in diagnosis and treatment of neuropsychiatric lupus
Schenck Neuropathology of REM sleep behavior disorder
RU2822604C1 (ru) Физиологически активное вещество srfm как биомаркер крови для диагностики нейродегенеративных нарушений и заболеваний человека
US20260110700A1 (en) Methods for remote blood collection, extraction and analysis of neuro biomarkers

Legal Events

Date Code Title Description
FZDE Discontinued